Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission
/in Dendritic Cells, International Publications, Ovarian Cancer /von 2011-10-22 / Cancer Immunol. Immunother. 2012 May;61(5):629-41Combination therapy of renal cell carcinoma or breast cancer patients with dendritic cell vaccine and IL-2: results from a phase I/II trial
/in Breast Cancer, Dendritic Cells, Hypernephroma, International Publications /von 2011-10-20 / J Transl Med 2011 Oct;9:178Improved efficacy of therapeutic vaccination with dendritic cells pulsed with tumor cell lysate against hepatocellular carcinoma by introduction of 2 tandem repeats of microbial HSP70 peptide epitope 407-426 and OK-432
/in Dendritic Cells, Hepatocellular Carcinoma, International Publications /von 2011-10-18 / Int. Immunopharmacol. 2011 Dec;11(12):2200-7Induction of tolerogenic dendritic cells by IL-6-secreting CT26 colon carcinoma
/in Colorectal Cancer, Dendritic Cells, International Publications /von 2011-10-15 / Immunopharmacol Immunotoxicol 2012 Jun;34(3):465-9Importance of retinoic acid-inducible gene I and of receptor for type I interferon for cellular resistance to infection by Newcastle disease virus
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2011-10-04 / Int. J. Oncol. 2012 Jan;40(1):287-98Current vaccination strategies for prostate cancer
/in Dendritic Cells, International Publications, Prostate Cancer /von 2011-10-03 / Eur. Urol. 2012 Feb;61(2):290-306Proving the principle: dendritic cell-based vaccines in urogenital cancers
/in Dendritic Cells, Hypernephroma, International Publications, Prostate Cancer /von 2011-10-01 / Expert Rev Vaccines 2011 Oct;10(10):1355-7
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de